Biogen Idec - O-STA

sreda, 22. 3. 2023

10.08.2011 09:44
Biogen Idec in Abbott naznanjata zelo dobre rezultate prve registracijske raziskave za Daclizumab HYP pri recidivno-remitentni multipli sklerozi
12.04.2011 13:09
Biogen Idec razkriva zelo dobre rezultate prve raziskave tretje stopnje oralnega BG-12 (DIMETIL FUMARAT) pri multipli sklerozi
07.10.2010 12:08
Biogen Idec na področju multiple skleroze z več kot 45 podatkovnimi predstavitvami na 26. letnem kongresu Evropskega odbora za zdravljenje in raziskave multiple skleroze vodi v svetovnem merilu
07.06.2006 10:05
FDA odobrila vnovič uvedbo TYSABRI(R) za zdravljenje ponovne obolelosti za multiplo sklerozo
18.11.2005 09:11
Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI(R) in Multiple Sclerosis
12.09.2005 08:23
Biogen Idec objavil spremembo uprave
09.09.2005 08:24
Biogen Idec Announces Strategic Initiative to Drive Long-Term Growth and Accelerate Business Development Activities; Plan Expected to Deliver Annualized Savings of $200 million to $300 million
09.08.2005 10:34
Novost pri varnostni evalvaciji zdravila
17.05.2005 14:46
Biogen Idec Identifies Molecule That May Be Key to Central Nervous System Repair and Regeneration
17.05.2005 07:50
Druge letne nagrade za "vodje upanja" za priznanje odločenosti in inovativnosti oseb z multiplo sklerozo
14.04.2005 08:02
Positive One-Year Data From SENTINEL Trial Evaluating Addition of TYSABRI to AVONEX Presented at American Academy of Neurology Meeting; Data from GLANCE Safety Study Also Presented
13.04.2005 08:03
Two-Year Monotherapy Data Support Positive One-Year Efficacy Findings and Show Significant Reduction in Risk of Disability Progression
07.04.2005 14:00
BG-12 Psoriasis Study Meets Primary Endpoint; Oral Compound Also Being Studied for MS in Phase II Trial
31.03.2005 08:32
Elan and Biogen Idec Announce TYSABRI Update
10.03.2005 09:10
Biogen Idec Announces Management Change
04.03.2005 08:59
Biogen Idec and Elan Announce Update on Tysabri-R-
01.03.2005 13:05
Biogen Idec in Elan napovedala začasen umik zdravila TYSABRI-R-
17.02.2005 08:40
TYSABRI-R- Two-Year Monotherapy Trial Demonstrates Significant Impact on Disability Progression and Relapse Rate in Multiple Sclerosis
22.12.2004 14:57
Biogen Idec in Elan napovedala primerjalno študijo o učinkovitosti in varnosti zdravil TYSABRI in Rebif ZUG,
21.12.2004 14:44
Biogen Idec and Elan Announce Head-to-Head Study Comparing Safety and Efficacy of TYSABRI-R- to Rebif-R-
24.11.2004 09:35
FDA Grants Accelerated Approval of TYSABRI, Formerly ANTEGREN, For the Treatment of Multiple Sclerosis Business
08.11.2004 09:30
ANTEGREN One-Year Data from Phase III AFFIRM Study Showed Compelling Results in Meeting Primary Endpoint in Multiple Sclerosis